Rare NUP98::PRRX1 fusion transcript in a therapy-related acute myeloid leukemia associated with del(7q) following chemotherapy for diffuse large B-cell lymphoma

Therapy-related acute myeloid leukemia (t-AML) is a serious adverse consequence in cancer treatment, including chemotherapy, radiation therapy, or immunosuppressive agents, accounting for 7% of adult AML [1,2]. The two most common leukemia-causing cytotoxic drugs include alkylating agents and topoisomerase-II inhibitors. The majority of alkylating agents-related leukemias have a longer latency of 5 –10 years and typically have a total or partial deletion of chromosome 5 [-5/del(5q)] and chromosome 7 [-7/del(7q)] and/or complex karyotype and are often present with prior myelodysplastic syndrome (MDS) and poor prognosis.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research